Taro Pharmaceutical Industries Ltd. reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was USD 130.5 million compared to USD 131.99 million a year ago. Net loss was USD 2.81 million compared to net income of USD 23.32 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to basic earnings per share from continuing operations of USD 0.62 a year ago.
For the six months, sales was USD 287.16 million compared to USD 279.1 million a year ago. Net income was USD 11.27 million compared to USD 4.55 million a year ago. Basic earnings per share from continuing operations was USD 0.3 compared to USD 0.12 a year ago.